71532Children's Hospital of Soochow University, Suzhou, China.
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221087830. doi: 10.1177/15330338221087830.
Increasing evidence has revealed the valuable diagnostic and prognostic applications of dysregulated microRNAs (miRNAs) in hepatoblastoma (HB), the most common hepatic malignancy during childhood. However, these results are inconsistent and remain to be elucidated. In the present study, we aimed to systematically compile up-to-date information regarding the clinical value of miRNAs in HB. Articles concerning the diagnostic and prognostic value of single miRNAs for HB were searched from databases. The sensitivity (SEN), specificity (SPE), positive and negative likelihood ratios (PLR and NLR), diagnostic odds ratio (DOR), area under the curve (AUC), and hazard ratios (HRs) were separately pooled to explore the diagnostic and prognostic performance of miRNA. Subgroup and meta-regression analyses were further carried out only in the event of heterogeneity. In all, 20 studies, involving 264 HB patients and 206 healthy individuals, met the inclusion criteria in the 6 included literature articles. For the diagnostic analysis of miRNAs in HB, the pooled SEN and SPE were 0.76 (95% CI: 0.72-0.80) and 0.75 (95% CI: 0.70-0.80), respectively. Moreover, the pooled PLR was 2.79 (95% CI: 2.12-3.66), NLR was 0.34 (95% CI: 0.26-0.45), DOR was 10.24 (95% CI: 6.55-16.00), and AUC was 0.83, indicating that miRNAs had moderate diagnostic value in HB. For the prognostic analysis of miRNAs in HB, the abnormal expressions of miR-21, miR-34a, miR-34b, miR-34c, miR-492, miR-193, miR-222, and miR-224 in patients were confirmed to be associated with a worse prognosis. The pooled HR was 1.74 (95% CI: 1.20-2.29) for overall survival and 1.74 (95% CI: 1.31-2.18) for event-free survival, suggesting its potential as a prognostic indicator for HB. To the best of our knowledge, this is the first comprehensive systematic review and meta-analysis that examines the diagnostic and prognostic role of dysregulated miRNAs in HB patients. The combined meta-analysis results supported the previous individual finds that miRNAs might provide a new, noninvasive method for the diagnostic and prognostic analyses of HB.
越来越多的证据表明,失调的 microRNAs(miRNAs)在肝母细胞瘤(HB)中具有有价值的诊断和预后应用,HB 是儿童时期最常见的肝恶性肿瘤。然而,这些结果并不一致,仍有待阐明。在本研究中,我们旨在系统地汇集有关 miRNAs 在 HB 中临床价值的最新信息。从数据库中搜索了关于单个 miRNAs 对 HB 的诊断和预后价值的文章。分别汇总灵敏度(SEN)、特异性(SPE)、阳性和阴性似然比(PLR 和 NLR)、诊断优势比(DOR)、曲线下面积(AUC)和危险比(HRs),以探讨 miRNA 的诊断和预后性能。只有在存在异质性的情况下,才进一步进行亚组和荟萃回归分析。
总之,在纳入的 6 篇文献中,有 20 项研究,涉及 264 名 HB 患者和 206 名健康个体,符合纳入标准。对于 miRNA 在 HB 中的诊断分析,汇总的 SEN 和 SPE 分别为 0.76(95%CI:0.72-0.80)和 0.75(95%CI:0.70-0.80)。此外,汇总的 PLR 为 2.79(95%CI:2.12-3.66),NLR 为 0.34(95%CI:0.26-0.45),DOR 为 10.24(95%CI:6.55-16.00),AUC 为 0.83,表明 miRNA 在 HB 中具有中等诊断价值。对于 miRNA 在 HB 中的预后分析,证实患者中 miR-21、miR-34a、miR-34b、miR-34c、miR-492、miR-193、miR-222 和 miR-224 的异常表达与预后不良相关。汇总的 HR 为 1.74(95%CI:1.20-2.29)用于总生存,1.74(95%CI:1.31-2.18)用于无事件生存,表明其作为 HB 预后指标的潜力。
据我们所知,这是第一项全面的系统评价和荟萃分析,检查了失调的 miRNAs 在 HB 患者中的诊断和预后作用。联合荟萃分析结果支持之前的个别发现,即 miRNAs 可能为 HB 的诊断和预后分析提供一种新的非侵入性方法。